Did you know?
ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.
Free Newsletter
Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!
Free Report
Shanghai Pharma is seeking to acquire a mid-sized US or...
Shanghai Duyiwei Biotechnology, a subsidiary of Gansu...
Abcam will pay $170 million to buy Epitomics, a US mAb...
China plans to spend $11.8 billion to increase biopharma...
Hangzhou Tigermed Consulting, a clinical-stage CRO,...
WuXi AppTec and MedImmune, an AstraZeneca subsidiary,...
Cardinal Health, a US drug distributor, spent $120...
Syros Pharmaceuticals of Boston raised $30 million to...
Shanghai Fosun Pharma, Chindex and a private equity...
Zhejiang Hisun Pharma contributed 75 drug products to...
ChinaBio® News
Greg Scott Interviewed at BIO-Europe Spring
How to bring your China assets to China in 8 minutes
"Mr. Bio in China."
Mendelspod Interview
Multinational pharma held to a higher standard in China
